Muna Therapeutics ApS: Financial statements 2022
CVR: 41142871
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
Muna Therapeutics ApS (CVR 41142871) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -98,234,040 and a net result of DKK -127,682,346 compared with DKK -61,518,260 the year before. Equity in the 2022 report amounted to DKK 202,044,949. The solvency ratio was 81.6%. The company had 16 employees in the financial year.
- Gross Profit
- DKK -98,234,040
- Profit/Loss
- DKK -127,682,346
- Equity
- DKK 202,044,949
- Total Assets
- DKK 247,517,682
- Employees
- 16
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | -98.2 mio. | -127.7 mio. | 202 mio. | 16 |
| 2021 | - | -49.7 mio. | -61.5 mio. | 162.3 mio. | 7 |
| 2020 | - | -7.3 mio. | -7.4 mio. | 16.7 mio. | 3 |
Official annual report
Keep an eye on Muna Therapeutics ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
As of June 30, 2022, is registered as an owner of Muna Therapeutics ApS with an ownership share of 5%.
As of June 30, 2022, is registered as an owner of Muna Therapeutics ApS with an ownership share of 5%.
As of June 30, 2022, is registered as an owner of Muna Therapeutics ApS with an ownership share of 15%.
Muna Therapeutics ApS has published its annual report for 2021. Gross profit came to DKK -49,692,746, and the net result was DKK -61,518,260.
As of June 1, 2022, Eileen Elizabeth McGuire has joined the board of directors of Muna Therapeutics ApS.
As of June 1, 2022, Isaac Ciechanover has left the board of directors of Muna Therapeutics ApS.
About Muna Therapeutics ApS
Muna Therapeutics ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2020. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Michel Marcel A. Detheux. The board consists of Donald William Nicholson (chair), Camilla Petrycer Hansen, Cillian King and Eileen Elizabeth McGuire. The company's owners include Novo Holdings A/S, Sanofi Foreign Participations B.V. and Axxam S.p.A.. The company has 18 employees (2026). In 2025, the company reported a gross profit of DKK -60,636,000 and a net result of DKK -125,695,000 compared with DKK -173,625,357 the year before. Equity in the 2025 report amounted to DKK -120,338,000.